Deep TMS for major depression, interim post-marketing analysis of 1040 patients.

Abstract

Post-treatment (1/27/ 2020) Apathy T-score: 33 47 Disinhibition T-score: 35 43 Executive Dysfunction Tscore: 34 43 FrSBe e Subscale Description Apathy (A) Problems with initiation, psychomotor retardation, spontaneity, drive, persistence, loss of energy and interest, lack of concern about self-care and/or blunted affective expression. Disinhibition (D) Problems with inhibitory control such as impulsivity, hyperactivity, socially inappropriate behavior and poor conformity to social conventions. Executive Dysfunction (E) Problems with sustained attention, working memory, organization, planning, future orientation, sequencing, problem solving, insight, mental flexibility, self-monitoring of ongoing behavior and/or the ability to benefit from feedback or modify behavior following errors.

Pursuing personalized medicine for depression by targeting the lateral or medial prefrontal cortex with Deep TMS

“…Both H-Coils induced similar decrease of depression and anxiety levels, similar increase in quality of life, and similarly high response and remission rates in these MDD patients. As expected from a study including two active arms, response and remission rates were higher than those achieved in the original sham-controlled study that led to the clearance of the H1 Coil by the FDA (7), and were similar to those of post-marketing assessments for the efficacy of the H1 Coil in depressive patients (48). As such, the results obtained here may approximate those expected in real-world clinical practice.…”